Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Finland (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Anti-Lambda FITC
      Product Details
      Down Arrow Up Arrow


      BD™
      IGL; IGL@; Ig λ; Immunoglobulin lambda
      Human
      Mouse BALB/c IgG1, λ
      Human IgA1-λ myeloma Protein
      Flow cytometry
      12.5 μg/mL
      20 μL
      3535,931
      Phosphate buffered saline with gelatin and 0.1% sodium azide.
      CE_IVD


      Preparation And Storage

      The antibody reagent is stable until the expiration date shown on the label when stored at 2°C to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

      Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

      Show More blue down arrow Show Less blue up arrow
      347247 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      1-155-2

      The Anti-Lambda antibody, clone 1-155-2, is derived from the hybridization of P3-X63-Ag8.653 mouse myeloma cells with cells from BALB/cJ mice immunized with human IgA1-λ myeloma protein.

      The Anti-Lambda antibody specifically recognizes lambda light chains of human immunoglobulins.

      347247 Rev. 1
      Format Details
      Down Arrow Up Arrow
      FITC
      Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      FITC
      Blue 488 nm
      494 nm
      518 nm
      347247 Rev.1
      Citations & References
      Down Arrow Up Arrow

      Development References (17)

      1. Ault KA. Flow cytometric evaluation of normal and neoplastic B cells. In: Rose NR, Friedman H, Fahey JL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clinical Laboratory Immunology. 3rd ed.. Washington, DC: American Society for Microbiology; 1986:247-253. View Reference
      2. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
      3. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. NCCLS document H42-A. 1998. (Biology).
      4. Clinical and Laboratory Standards Institute. 2005. (Biology).
      5. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
      6. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma.. Blood. 1986; 68(1):1-31. (Biology). View Reference
      7. Fukushima PI, Nguyen PK, O'Grady P, Stetler-Stevenson M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia.. Cytometry. 1996; 26(4):243-52. (Biology). View Reference
      8. Harris NL, Data RE. The distribution of neoplastic and normal B-lymphoid cells in nodular lymphomas: use of an immunoperoxidase technique on frozen sections.. Hum Pathol. 1982; 13(7):610-7. (Biology). View Reference
      9. Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
      10. Kubagawa H, Gathings WE, Levitt D, Kearney JF, Cooper MD. Immunoglobulin isotype expression of normal pre-B cells as determined by immunofluorescence.. J Clin Immunol. 1982; 2(4):264-9. (Biology). View Reference
      11. Meis JM, Osborne BM, Butler JJ. A comparative marker study of large cell lymphoma, Hodgkin's disease, and true histiocytic lymphoma in paraffin-embedded tissue.. Am J Clin Pathol. 1986; 86(5):591-9. (Biology). View Reference
      12. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.. Am J Pathol. 1987; 128(1):181-201. (Biology). View Reference
      13. Smith BR, Weinberg DS, Robert NJ, et al. Circulating monoclonal B lymphocytes in non- Hodgkin's lymphoma. N Engl J Med. 1984; 311:1476-1481. (Biology).
      14. Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
      15. Tubbs RR, Sheibani K, Weiss RA, Sebek BA, Deodhar SD. Tissue immunomicroscopic evaluation of monoclonality of B-cell lymphomas: comparison with cell suspension studies.. Am J Clin Pathol. 1981; 76(1):24-8. (Biology). View Reference
      16. Têtu B, Manning JT, Ordóñez NG. Comparison of monoclonal and polyclonal antibodies directed against immunoglobulin light and heavy chains in non-Hodgkin's lymphoma.. Am J Clin Pathol. 1986; 85(1):25-31. (Biology). View Reference
      17. Weinberg DS, Pinkus GS, Ault KA. Cytofluorometric detection of B cell clonal excess: a new approach to the diagnosis of B cell lymphoma.. Blood. 1984; 63(5):1080-7. (Biology). View Reference
      View All (17) View Less
      347247 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For In Vitro Diagnostic Use.

       

      23-22942-00

      Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.

      Website Feedback